- Amplicore Inc., a Cincinnati, OH-based early-stage biopharmaceutical company, closed its $4m seed round of funding
- The round was led by Photon Fund, with participation from Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE Capital
- Amplicore is a biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases
- The company intends to use the funds to complete the preclinical development of its two leading products, AM3101 and AM1101, and position itself for the next round of financing
- Amplicore is also leveraging a study on the healing of acute meniscal tear after surgical repair, supported by a grant from the US Department of Defense (DoD)
- The company is also developing AM1101 as a treatment for osteoarthritis (OA) designed to reduce joint OA pain, inhibit cartilage degradation
